Blog
RSS FeedPosted by Michael Wonder on 06 Nov 2018
Should a drug’s value depend on the disease or population it treats? Insights from ICER’s value assessments
6 November 2018 - The ICER, a private, nonprofit organisation that evaluates the clinical and economic value of prescription drugs, ...
Posted by Michael Wonder on 31 Oct 2018
ICER posts draft scoping document for the assessment of esketamine for treatment-resistant depression
31 October 2018 - Document open to public comment until 20 November 2018 ...
Posted by Michael Wonder on 31 Oct 2018
ICER posts draft scoping document for the assessment of siponimod for the treatment of secondary progressive multiple sclerosis
31 October 2018 - Document open to public comment until 20 November 2018. ...
Posted by Michael Wonder on 30 Oct 2018
Institute for Clinical and Economic Review to publish upcoming assessment on treatments for peanut allergy
30 October 2018 - Report will be subject of CTAF meeting in June 2019; open input now being accepted until 15 ...
Posted by Michael Wonder on 26 Oct 2018
Institute for Clinical and Economic Review report finds extended-release treatments for opioid use disorder provide only marginal benefits over generic alternatives, at significantly higher prices
25 October 2018 - ICER report includes value-based annual price ranges for Probuphine, Vivitrol, and CAM2038. ...
Posted by Michael Wonder on 24 Oct 2018
Institute for Clinical and Economic Review ends assessment of canakinumab for atherosclerosis
24 October 2018 - The Institute for Clinical and Economic Review today announced that it will not proceed with its comparative ...
Posted by Michael Wonder on 11 Oct 2018
ICER finds treatments prevent hereditary angioedema attacks, but cost-effectiveness uncertain and sensitive to frequency of attacks
11 October 2018 - As with all treatments for ultra-rare conditions, judgments of overall value require consideration of the broader patient ...
Posted by Michael Wonder on 10 Oct 2018
Institute for Clinical and Economic Review to publish upcoming assessments on treatments for secondary progressive multiple sclerosis, treatment-resistant depression
10 October 2018 - Both reports will be subject of Midwest CEPAC meeting in May 2019. ...
Posted by Michael Wonder on 04 Oct 2018
ICER final report highlights uncertainty in long-term safety and effectiveness of new treatments for hereditary transthyretin amyloidosis, discusses options for insurance coverage criteria
4 October 2018 - The ICER today released a final evidence report and report-at-a-glance on inotersen (Akcea Therapeutics) and patisiran ...
Posted by Michael Wonder on 04 Oct 2018
ICER review highlights the clinical benefits of using anti-androgen therapies to treat earlier stage prostate cancer
4 October 2018 - Midwest CEPAC’s vote on value reflects uncertainty around duration of treatment with anti-androgens. ...
Posted by Michael Wonder on 27 Sep 2018
Paying for value: US state of play
27 September 2018 - Drug pricing in the US is a perennial topic, which is no surprise given the the ...
Posted by Michael Wonder on 25 Sep 2018
ICER releases draft evidence report on biologic treatments for asthma
24 September 2018 - Public comment period now open until 22 October 2018; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 20 Sep 2018
Will CVS Caremark make ICER the American NICE?
20 September 2018 - Rationing of some sort is part and parcel of every healthcare system. Simply put, it refers to ...
Posted by Michael Wonder on 07 Sep 2018
ICER releases draft evidence report on medications for treatment of opioid use disorder
7 September 2018 - Public comment period now open until 4 October 2018; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 30 Aug 2018
ICER finds current list price of patisiran for amyloidosis far exceeds standard cost-effectiveness levels
29 August 2018 - Report also evaluates evidence on inotersen; during public meeting of Midwest CEPAC on 13 September, a policy ...